Table 3.
Antithrombotic treatment versus guideline recommended therapy
| Actual treatment | Guideline recommendations a | ||||
|---|---|---|---|---|---|
| Warfarin | Warfarin OR Aspirin | Aspirin | Neither | Total | |
| All subjects (n = 219) | |||||
| All Subjects | |||||
| Warfarin AND Aspirin | 3 | 0 | 0 | 0 | 3 |
| Warfarin | 39 | 1 | 0 | 0 | 40 |
| Aspirin | 71 | 3 | 1 | 0 | 75 |
| Neither | 91 | 4 | 6 | 0 | 101 |
| Total | 204 | 8 | 7 | 0 | 219 |
| Subjects with known atrial fibrillation (n = 150) | |||||
| Subjects with known AF | |||||
| Warfarin AND Aspirin | 2 | 0 | 0 | 0 | 2 |
| Warfarin | 37 | 1 | 0 | 0 | 38 |
| Aspirin | 53 | 2 | 1 | 0 | 56 |
| Neither | 52 | 0 | 2 | 0 | 54 |
| Total | 144 | 3 | 3 | 0 | 150 |
a
Notes: Based on the guidelines presented by Laupacis et al 1998.